Evaluation Of The Effect Of SGLT-2 Inhibitors On Atrial Fibrillation Recurrence In Diabetic Patients

Bursa Postgraduate Hospital120 enrolled

Overview

Consecutive DCCV was performed until to achieve 120 patients in SR (60 DM patients who used SGLT-2 inhibitors and 60 DM patients who did not use SGLT-2 inhibitors). Patients defined as SGLT-2 inhibitor user group and control group. The two groups were monitored for AF recurrence on the first day, then at one, three, and six months after CV.

Study Type

OBSERVATIONAL

Enrollment

120

Conditions

Diabetes Mellitus Atrial Fibrillation (AF)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients \> 18 years and \< 90 years, * Patient diagnosed with DM * Patient underwent electrical cardioversion due to AF and was restored to sinus rhythm Exclusion Criteria: * patient who are not suitable for anticoagulant use, * have thyroid dysfunction, * glomerular filtration rate ≤ 25 ml/min/1.73 m², * patients whose sinus rhythm cannot be achieved with electrical cardioversion, * malignancy patients, * patients with acute or chronic inflammatory disease, * patients with peripheral artery disease, * patients with pacemakers, * patients with advanced valve stenosis or insufficiency, * patients who have had coronary bypass surgery, * patients with percutaneous or surgical bioprosthesis or metallic valve surgery.

Locations (1)

Bursa Yüksek İhtisas Hastanesi

Bursa, Turkey (Türkiye)

Outcomes

Primary Outcomes

Atrial fibrillation recurrence

Time frame: six month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.